Autism and Endometriosis Therapeutic Pipeline (Company and Drugs Profiles) Review H2 2014

DALLAS, October 18, 2014 /PRNewswire/ --

RnRMarketResearch.com adds "Autism - Pipeline Review, H2 2014" and "Endometriosis - Pipeline Review, H2 2014" market research reports to its store. The reports provide an overview of the Autism's and Endometriosis's therapeutic pipeline. They cover comprehensive information on the therapeutic development for Autism and Endometriosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. These research reports also review key players involved in the therapeutic development for Autism & Endometriosis and special features on late-stage and discontinued projects.

Autism - Pipeline Review, H2 2014 

Autism is a neurodevelopmental disorder characterized by impaired social interaction, verbal and non-verbal communication, and by restricted and repetitive behavior. The diagnostic criteria require that symptoms become apparent before a child is three years old. Autism affects information processing in the brain by altering how nerve cells and their synapses connect and organize; how this occurs is not well understood. It is one of three recognized disorders in the autism spectrum (ASDs), the other two being Asperger syndrome, which lacks delays in cognitive development and language, and pervasive developmental disorder, not otherwise specified (commonly abbreviated as PDD-NOS), which is diagnosed when the full set of criteria for autism or Asperger syndrome are not met. Complete Report with Table of Content Available @ http://www.rnrmarketresearch.com/autism-pipeline-review-h2-2014-market-report.html .

Autism has a strong genetic basis, although the genetics of autism are complex and it is unclear whether ASD is explained more by rare mutations, or by rare combinations of common genetic variants. In rare cases, autism is strongly associated with agents that cause birth defects. Controversies surround other proposed environmental causes, such as heavy metals and pesticides. The prevalence of autism is about 1-2 per 1,000 people worldwide, and it occurs four to five times more often in boys than girls. The Centers for Disease Control and Prevention (CDC) report 1.5% of children in the United States (one in 68) are diagnosed with ASD as of 2014, a 30% increase from one in 88 in 2012. The number of people diagnosed with autism has been increasing dramatically since the 1980s, partly due to changes in diagnostic practice and government-subsidized financial incentives for named diagnoses; the question of whether actual prevalence has increased is unresolved.

Autism - Companies Involved in Therapeutics Development: 

F. Hoffmann-La Roche Ltd., Sumitomo Dainippon Pharma Co., Ltd., Egenix, Inc., Novartis AG, Merz Pharma GmbH & Co. KgaA, Mitsubishi Tanabe Pharma Corporation, Teva Pharmaceutical Industries Limited, BrainStorm Cell Therapeutics Inc., Avanir Pharmaceuticals, Inc., Curemark, LLC, Coronado Biosciences, Inc., Omeros Corporation, Intra-Cellular Therapies, Inc., Cellceutix Corporation, Heptares Therapeutics Ltd., Edison Pharmaceuticals, Inc., Otsuka Holdings Co., Ltd., Reviva Pharmaceuticals Inc., Naurex, Inc., Mnemosyne Pharmaceuticals, Inc., BioCrea GmbH, Saniona AB, Confluence Pharmaceuticals LLC, MedDay. Order a Purchase copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=231449 .

Endometriosis - Pipeline Review, H2 2014 

Endometriosis is a gynecological condition in which cells from the lining of the uterus (endometrium) appear and flourish outside the uterine cavity, most commonly on the membrane which lines the abdominal cavity, the peritoneum. The uterine cavity is lined with endometrial cells, which are under the influence of female hormones. Endometrial cells in areas outside the uterus are also influenced by hormonal changes and respond in a way that is similar to the cells found inside the uterus. Symptoms of endometriosis are pain and infertility. The pain often is worse with the menstrual cycle and is the most common cause of secondary dysmenorrhea. Complete Report with Table of Content Available @ http://www.rnrmarketresearch.com/endometriosis-pipeline-review-h2-2014-market-report.html .

Endometriosis is typically seen during the reproductive years; it has been estimated that endometriosis occurs in roughly 6-10% of women. Symptoms may depend on the site of active endometriosis. Its main but not universal symptom is pelvic pain in various manifestations. There is an established association between endometriosis and infertility. Endometriosis has a significant social and psychological impact. There is no cure for endometriosis, but it can be treated in a variety of ways, including pain medication, hormonal treatments, and surgery.

Endometriosis - Companies Involved in Therapeutics Development: 

Euroscreen S.A., Takeda Pharmaceutical Company Limited, Neurocrine Biosciences, Inc., Astellas Pharma Inc., Kissei Pharmaceutical Co., Ltd., SK Chemicals Co., Ltd., Bayer AG, Addex Therapeutics Ltd, Evotec AG, ValiRx Plc, Repros Therapeutics Inc., Dongkook Pharmaceutical Co., Ltd., Lipicard Technologies Limited, Orphagen Pharmaceuticals, Inc., Peptron, Inc., PregLem SA, EndoCeutics, Inc., Isifer AB, ElexoPharm GmbH, APAvadis Biotechnologies Srl, AbbVie Inc., Forendo Pharma Oy. Order a Purchase Copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=231447 .

Reasons to buy 

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Autism
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Autism pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse more reports on Therapeutics Market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics .

About Us: 

RnRMarketResearch.com provides syndicated market research reports (500,000+) and in-depth studies of over 5000 micro markets. Not limited to any one industry, we offer research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact:  

Ritesh Tiwari

TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252

Tel: +1-888-391-5441
sales@rnrmarketresearch.com